false
0001677077
false
false
false
false
0001677077
2026-11-18
2026-11-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
___________________________________________________________________
Date of Report (Date of earliest event reported): November 18, 2026
ALZAMEND NEURO, INC.
(Exact name of registrant as specified in its
charter)
| Delaware |
|
001-40483 |
|
81-1822909 |
(State or other jurisdiction of
incorporation or organization) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
3480 Peachtree Road NE, Second Floor, Suite
103, Atlanta, GA 30326
(Address of principal executive offices) (Zip
Code)
(844) 722-6333
(Registrant's telephone number, including area
code)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| o | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock, $0.0001 par value |
|
ALZN |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 7.01 | Regulation FD Disclosure. |
On November 18, 2026, Alzamend
Neuro, Inc. will present at the annual meeting of the Society for Neuroscience. A copy of the presentation, which is furnished herewith
as Exhibit 99.1, is incorporated by reference herein.
In accordance with General
Instruction B.2 of Form 8-K, the information under this item and Exhibit 99.1 shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. This report
will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of
Regulation FD.
The Securities and Exchange
Commission encourages registrants to disclose forward-looking information so that investors can better understand the future prospects
of a registrant and make informed investment decisions. This Current Report on Form 8-K and exhibits may contain these types of statements,
which are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and which
involve risks, uncertainties and reflect the Registrant’s judgment as of the date of this Current Report on Form 8-K. Forward-looking
statements may relate to, among other things, operating results and are indicated by words or phrases such as “expects,” “should,”
“will,” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual
results to differ materially from those anticipated at the date of this Current Report on Form 8-K. Investors are cautioned not to rely
unduly on forward-looking statements when evaluating the information presented within.
| Item 9.01 | Financial Statements and Exhibits. |
| Exhibit No. |
|
Description |
| |
|
|
| 99.1 |
|
Society for Neuroscience Presentation |
| 101 |
|
Pursuant to Rule 406 of Regulation S-T, the cover page is formatted in Inline XBRL (Inline eXtensible Business Reporting Language). |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
ALZAMEND NEURO, INC. |
| |
|
| |
|
| Dated: November 18, 2026 |
/s/ David J. Katzoff |
|
| |
David J. Katzoff
Chief Financial Officer |
-3-
Exhibit 99.1
&' CTRU Lithium is considered a gold-standard treatment for bipolar I disorder, and is also used therapeutically in major depressive disorder, schizophrenia, Alzheimer's disease, and post-traumatic stress disorder. However, its clinical utility is constrained by a narrow therapeutic window for inorganic lithium salts which need careful monitoring to manage renal, thyroid, and other systemic toxicity risks. AL001 is a novel ionic lithium salicylate salt co-crystallized with co-former L-proline designed for better brain delivery with less systemic exposure than inorganic salts1. Pharmacological resting-state fMRI provides a noninvasive approach to characterizing drug-associated changes in functional brain networks2. In the study, we used ultra-high-field resting-state fMRI to explore changes in brain functional connectivity following AL001 and conventional lithium carbonate treatment (Li2C03) in healthy participants. Sequence A Screening procedures include medical and surgical history, physical and neurological examinations, vital signs, a 12-lead ECG, and clinical laboratory testing. Eligible participants are admitted into the MGH Translational and Clinical Research Center (TCRC) for a 14-day dosing period, where they are randomized to receive either lithium carbonate or AL001. This dosing period is followed by a 28-hour inpatient stay at the Martinas Center, during which 27 PK blood samples are drawn, and 7 H-/Li-MRI-MRSI scans are performed. Six healthy participants completed baseline and two post-treatment imaging visits following two-week treatment with AL001 and the standard-of-care lithium carbonate. Resting-state BOLD images were acquired with a TR of 860 ms and 1.8-mm isotropic resolution. Data were preprocessed using fMRIPrep3 and de noised using XCP-D4 with 24 motion regressors, 1 O aCompCor components, 0.008-0.09 Hz bandpass filtering, and motion censoring (FD> 0.3 mm). Parcel-wise functional connectivity (FC) was estimated using Pearson correlations and Fisher-z transformation with the 4S156Parcels atlas4?5, combining 100 cortical parcels with 56 subcortical and cerebellar parcels. FC changes relative to baseline were characterized at the parcel and network levels. Exploratory network-level comparisons were performed using two-sided Wilcoxon signed-rank tests with Benjamini-Hochberg false discovery rate correction across 66 network pairs per contrast. 0.7 0.6 0.5 0.2 o., ?som~ ?OOr1A1111 -~ ?I.Wolloe ?COAi ?Dtld ?~ ?rl'lflUJl'iut ?M~ Fig 1B I Selected Network-Pair Connectivity Across Conditions Default -Default 0.5 0.45 04 0.35 -i 03 ~0--25 l;' i 0.2 0.15 o, 0.05 Cont ? Oetault ? ? ? ? 0.35 Default -OorsAttn 0.3 ·r 0.25 ? ? ? 0.05 ? ? I ?-o'-----------,----------·0.05'-----------L2 ' -~ U: 0.8 a g tt 0.6 ? i ~ 0.4 C E i 0.2 0.3S ~ 0.3 " C ? ~ 0.25 C ? ? g 0.2 u ~ I 0.15 ~ o., I ~ 0.05 0 -0.05 Baseline ? ? ? ? ? ? .. J -? ? ? ? ? ALOO> Concf11ion Li,co, Baseline ALOOl Li,CO, Condilion Baseline ALOOl Li,CO, Condition 1--+-HCIO --+-HC2 --+-HCS --+-HC6 --+-HC7 --+-HC9 o QChighliglited(>lM-6censored)I Figure 1C I Within-and Between-Network FC Across Conditions Baseline {n=6) ALOOl {n=4) ,.2 ,.2 ' ? ' ? ? 0.8 0.8 ? ® ® ® ? ® ? 0.6 -8 ?o o., 7!J ? , ? ? T ® ? ® ? .JD ® ® ? ? ?? ? ® ? ? @ .... ~ 0 ? ? -.... o., ? ? o., ? ? ? @ ~ ~ ? ? -@ @ ? ? ? ? ? ? .., ? ? -e ? 0.2 0.2 ? ? 0 0 ··/// jt J <f'#/ I'// C "' / c? V ~ .."f-c.f Baseline (n=6) ALOOl (n=4) 0.3S 0.3S ? ? 0.3 0.3 @ ? ? ? ? ' @ ? ? 0.25 ® 0.25 ? ? ® ? .., 0 ? ? ? @ ® ® ? ? 0.2 ® 0.2 ? .... -? ? ? ? ~ j -. ? ' r., ~ ~ .... ? 0.15 ® ~ ~ 0.15 -... ? ? ? ? ? ? ? ? ? f> ® ? ? ? ... ? ? o., ? ? ? ? o., ® ® ? ? @ ? ? ? ? ? ? ? ? ? ? ? ? ? 0.05 ? 0.05 ? .... ? , ? ? ? ? 0 0 -0.05 -0.05 ? .a ? @ ? -? ? ""?<F / / ii' J<f'#//// a / ;f ? J .."f-cl I ? lndiwlual scar, (netwark color) -Gmup mean 0 QC hi,ghllQl'led. Cltr"l$U > 1M61 Figure 2A. Group-Averaged Regional Homogeneity (ReHo) 0 ? ? ? 0 ? ? ? QC and Scan Inclusion: Scans with >20% censored volumes were excluded. Retained scans with >15% censored volumes were included in the analysis but highlighted for additional QC consideration. Final sample size: 6 subjects; Baseline n = 6, AL001 n = 4, Li2C03 n = 4. Fig1A. Group-Average FC Group-mean FC matrices across three conditions, organized by 11 networks (156 parcels). Pearson correlations were Fisher-z transformed before averaging and converted back to Pearson r for visualization. Fig 1 B. Selected Network-Pair Connectivity Across Conditions Exploratory paired Wilcoxon signed-rank tests were performed across 66 network pairs for each baseline-referenced contrast, with FDR correction. No network-pair changes survived FDR correction. Selected network pairs illustrate descriptive FC differences and individual variability across conditions. Li2C03 (n=4) ® ® ? Ii) ® ~ -® -? ? ~ ? ... ? ? @ ? -? Li2C03 (n=4) @ @ @ @ ® ® ? ? ? "' ? ? ? ? ? I ? ? " 0.6 ® ., ? ? @ ? ? ? ?? ? Figure 1 C. Network-Wise Within-and Between-Network FC Within-network FC was calculated by averaging unique connections among parcels in each within-network. Between-network FC was calculated as the edge-weighted mean of connections from each network to all external parcels. Individual dots represent scans; horizontal lines indicate group means . -Lithium Carbonate !3 -Baselin 0 0,9 -Figure 2B I Whole-Brain System Segregation Edge-pooled ? ? ? ? Re Ho measures local BOLD signal synchrony using Kendall's coefficient of concordance (W). XCP-D-derived ReHo maps (91 k grayordinates) were averaged across scans within each condition. ? ? ? @ Figure 2B. Whole-Brain System Segregation System segregation6 was calculated using pooled within-network (W) and between-network (B) FC across the 11 networks: Segregation = (W -B) / W Negative Fisher-z correlations were set to zero before averaging, following a positive-connectivity approach. Higher values indicate stronger within-network relative to between-network connectivity. ' !0.4 10.3 [ i 0.2 Ji o., 0 Baseline (n=6) ALOOl (n=4) I ? lntli\liollal scan -Group mean o QC highlighted I Figure 3A. Pairwise Functional Connectivity Changes o., 0.4 Figure 3A I FC Changes Relative to Baseline ALOOl. Baseline (n~) Li2C03 ? Baseline (n~) >.>:.= IJ.' ::i"~?·~i .;;, I I ... . ..--.. ' . ~µ:., w,µlql ~~F.e51f."f.0 CT ~.-'l'.!,',.:!.';.:.[:a,.:_?~?G._,.,j...c..;hl!.,.~t:....:/-..-C.l..' ,..µ;_~ ,.... -1-? ' ' ?? , ¢+'-~Pl-l!!,:h" c.'H'· +i-.-F"'..c::"1+;, ·-... 0.2 ., Within-subject FC differences (t.z) were calculated from Fisher-z-transformed correlations and averaged across participants. ·0,2 . ' ~ :, Heatmaps show AL001 -Baseline and Li2C03-Baseline, organized by 11 networks. ?0,4 .Q,6 ., t' ' ,_ .. , ... ? ·-. . .,. . . ·~ ,._ , .. ? ? Vis ? SomMot ? D«SAlln ? SalventAAn ? LJ'Mbic ? Com ? Defaul1 ? Subcoflital ? Thalamus ? HippAmyg ? Cerebellum Signed mean l!:. z Mean absolute ll!:. zl ALOOl ? Baseline Li2C03 -Baseline ALOOl -Baseline Li2C03 -Baseline Within? network 0 4 0 0 4 0 0 5 Between-network Figure 3B. Parcel-Wise FC Change Maps (45156 atlas) For each parcel, FC changes were averaged across connections within its network (excluding self-connections) or between networks. Two complementary measures were calculated for each participant before group averaging: ? Signed ~z: Mean connectivity change, preserving direction. ? Mean absolute ~z: Mean of absolute edge-wise changes, reflecting magnitude regardless of direction. Conclusion: We characterized resting-state brain functional connectivity across three conditions (AL001, Li2C03, baseline) using complementary network-level, parcel-wise, and spatial measures. Exploratory analyses revealed descriptive differences between the modulation of AL001 and Li2C03 on brain connectivity with inter-subject variability, but no network-pair changes survived FDR correction. Given the small sample size, these findings remain preliminary and warrant further investigation in a larger cohort. Reference: 2. 1. ClinicalTrials.gov. A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects. NCT06921590. https:/klinicaltrials,goy/study/NCT06921590. Khalili-Mahani N. Rom bouts SARB, van Osch MJP, et al. Biomarkers, designs, and interpretations of resting-state fMRI in translational pharmacological research: A review of state-of-the-art. challenges, and opportunities for studying brain chemistry. Hum Brain Mapp . 2017;38(4):2276-2325. doi:10.1002/hbm.23516. 3 . Esteban 0, Markiewicz CJ, Blair RW, et al. fMRIPrep: a robust preprocessing pipeline for functional MRI. Nat Methods. 2019;16:111-116. doi: 10.1038/s41592-018-0235-4. 4. Mehta K, Salo T, Madison TJ, et al. XCP-D: A robust pipeline for the post-processing of fMRI data. Imaging Neurosci. 2024;2. doi: 10.1162/imag_a_00257. 5. Schaefer A, Kong R, Gordon EM, et al. Local-global parcellation of the human cerebral cortex from intrinsic functional connectivity MRI. Cereb Cortex. 2018;28(9):3095-3114. doi:10.1093/cercor/bhx179. 6. Chan MY, Park DC, Savalia NK, Petersen SE, Wig GS. Decreased segregation of brain systems across the healthy adult lifespan. Proc Natl Acad Sci USA. 2014; 111 (46)-E5006. doi: 10.1073/pnas.1415122111. Acknowledgement: Funding, regulatory and protocol and support from the sponsor of the clinical trial, Alzamend Neuro Inc.